In this study, we described the clinical-biological characteristics of a series of pediatric LCH patients with MAS-HLH and analyzed the difference in treatment outcomes between targeted therapy (dabrafenib) and chemotherapy for BRAF-V600E-positive patients. The gene discussed is BRAF; the disease is Langerhans cell histiocytosis.